Skip to content

Cancer Fatigue Education Program

Development and Implementation of a Cancer Fatigue Education Program

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01278147
Enrollment
200
Registered
2011-01-17
Start date
2007-05-31
Completion date
2010-06-30
Last updated
2011-01-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patient With Histologically Confirmed Malignancy

Keywords

cancer, fatigue program education

Brief summary

The purpose of the present project is to develop, implement and evaluate a pilot regional patient education program on the management of one of the main side effects of chemotherapy in cancer patients, that is fatigue. A carer (doctor or nurse) trained in educational techniques will be responsible for the patient. The carer will first identify modes of behavior and competences that the patient must acquire in order to optimize his/her management of fatigue (educational diagnosis). An education program, based on a contract of goals will be proposed after this diagnosis phase. The expected results are, in the short-term, a significant reduction in the mean level of fatigue in patients receiving chemotherapy who benefited from individual educational management. In the longer term, the aim is to evaluate the impact of this program on patient quality of life and use of healthcare structures in comparison with conventional management.

Interventions

BEHAVIORALfatigue education program

the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.

Sponsors

Institut de Cancérologie de la Loire
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* \- Age\> 18 years. * Patient with histologically confirmed malignancy, during initial treatment with chemotherapy, followed or not by surgery, or the first week of radiotherapy. Patients with hematologic malignancy (including non-Hodgkin's lymphoma or Hodgkin's disease) may be included in the study, except for patients with leukemia. * Having a fatigue up during the week preceding the inclusion level measured by the average patient with 2 or more on a visual analogue scale (VAS) graded from 0 to 10 (0 expressing no fatigue and 10 the maximum fatigue imaginable ). * Volunteered to participate in PEPs Coping with fatigue. * Usually followed as outpatients. * Condition preserved (ECOG PS 2). * Available for all meetings of the educational program (5 sessions of 2 hours over a period of 5 weeks). * Able to read, write and understand French. * Resident (s) in a 50 km radius around the center investigator. * Can be contacted by phone. * Compulsory membership of a social security system. * Obtaining informed consent in writing, signed and dated.

Exclusion criteria

* \- Patient (e) with the inclusion anemia with a hemoglobin level below 10 g/100 mL. * Patient (e) having a documented history of cognitive or psychiatric disorders. * Patient (e) can not be followed for family, social, geographical or psychological. * Patient (e) deprived of their liberty by court or administrative

Design outcomes

Primary

MeasureTime frameDescription
Education program8 weeksThe main indicator of patient satisfaction after the education program will be the change during 8 weeks of follow-up in the mean fatigue score measured on a specific scale (FACT-F) (32).

Secondary

MeasureTime frameDescription
self-evaluation8 weeksOne secondary efficacy variables will comprise self-evaluation of patient quality of life measured using the SF-36 scale
healthcare structures8 weeksThe secondary efficacy variables will comprise evaluation of the use by patients of healthcare structures (phone calls, number of home visits, number of days of hospitalization, visits to emergency departments, other carers).

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026